Entry into a Material Definitive Agreement

On April 3, 2026 GT Biopharma, Inc., a Delaware corporation (the "Company"), reported to have entered into an Investigator Initiated Clinical Trial Agreement (the "Agreement") with the Regents of the University of Minnesota (the "University"), pursuant to which, the University shall sponsor an Investigational New Drug ("IND") application for IND 169118 GTB-5550 (the "Research Program") and shall serve as a sponsor investigator for a phase 1a/1b clinical trial entitled, "GTB-5550, a Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE), in Select Advanced Solid Tumors That Failed Prior Therapy," designed by University (the "Study"). The Research Program is being conducted for clinical research use. The budget for the Study, including without limitations, funding and resources, provides for up to approximately $3.8 million over the course of three years borne by the Company. The University and the Company will each have the right to publish the Study results. The Agreement may be terminated by the Company or the University at any time upon thirty days’ written notice to the other party, by the University immediately for health, welfare and safety reasons, or by either party if the other party materially breaches the Agreement, provided that the breaching party fails to cure such breach within thirty days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated by reference into this Item 1.01.

(Filing, GT Biopharma, APR 3, 2026, View Source [SID1234664207])

Breyangi CAR T-cell therapy has received approval for partial changes to its manufacturing and marketing authorization for "relapsed or refractory marginal zone lymphoma (MZL)" and "relapsed or refractory mantle cell lymphoma (MCL)".

On April 3, 2026 Bristol-Myers Squibb Company (Headquarters: Tokyo, Japan) today received approval for a partial amendment to the manufacturing and marketing authorization for its CD19-targeted CAR T-cell therapy, "Breyangi Injection" (generic name: lysokabutagen maralucell, hereinafter "Breyangi"), for the treatment of relapsed or refractory marginal zone lymphoma (hereinafter, MZL) and relapsed or refractory mantle cell lymphoma (hereinafter, MCL). This approval will allow Breyanzi to be offered as a treatment option for relapsed or refractory MCL regardless of the number of prior treatment lines, and for relapsed or refractory MZL from the third line of treatment onward.
This adds a new option to these disease areas where there remains a high level of unmet medical need.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MZL and MCL are both B-cell lymphomas that fall under the category of non-Hodgkin lymphoma. MZL is a subtype that accounts for about 7% of all non-Hodgkin lymphomas. While many patients achieve remission with initial treatment, relapses are not uncommon, and there has been a need for new treatment options that provide long-term, sustained therapeutic effects. In addition, some cases of MZL can progress to diffuse large B-cell lymphoma, which is a more aggressive form of lymphoma.

MCL is a highly malignant and rare form of non-Hodgkin lymphoma, accounting for approximately 3% of all non-Hodgkin lymphomas. It originates from cells that make up the "mantle zone" of the lymph nodes. The average age at diagnosis is in the mid-60s, and it is more common in the elderly. There is no established standard treatment for MCL that can be expected to cure the disease, and ultimately, disease progression or recurrence occurs. Treatment options for relapsed or refractory MCL are limited.

This approval is based on efficacy and safety results obtained in the MZL cohort of the international collaborative Phase II clinical trial (TRANSCEND FL trial) for patients with relapsed or refractory low-grade B-cell non-Hodgkin lymphoma, and in the MCL cohort of the overseas Phase I clinical trial (TRANSCEND NHL 001 trial) for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Angela Davis, Head of Research and Development at Bristol-Myers Squibb Company, stated:

"This approval further expands the indications for Breyange as a CD19-targeted CAR T-cell therapy for B-cell malignancies.
This new single-dose CAR T-cell therapy is highly significant for patients with relapsed or refractory MCL and MZL who have received multiple treatments.
Bristol-Myers Squibb will continue to drive the development and delivery of innovative cell therapies worldwide, aiming to bring long-term benefits to patients facing serious illnesses."

About the TRANSCEND FL trial (Marginal Zone Lymphoma (MZL))
The TRANSCEND FL trial is a phase II, open-label, multicenter study evaluating the efficacy and safety of Breyanzi. Cohort 4 (patients with MZL prior to two or more systemic therapies) includes 67 adult patients with relapsed or refractory indolent B-cell NHL (65 non-Japanese patients and 2 Japanese patients).

The primary endpoint is the overall response rate (ORR), while secondary endpoints include the complete response rate (CRR), duration of response (DOR), DOR in patients who achieved complete response (CR), progression-free survival (PFS), overall survival (OS), safety, and cytokinetics, among others.

In the efficacy analysis population of 66 patients (including 2 Japanese patients) treated with Breyanzi, the primary endpoint, the overall response rate (95% CI), was 95.5% (87.3-99.1), which was statistically significant against the threshold of 50% (p<0.0001). Both Japanese patients showed a response. The
safety profile was consistent with previously reported findings, and no new safety signals were observed.

About the TRANSCEND NHL 001 trial (Mantle cell lymphoma (MCL))
The TRANSCEND NHL 001 trial is a phase I, open-label, multicenter study evaluating the efficacy and safety of Breyanzi. The MCL cohort (patients with MCL prior to two or more systemic therapies) includes 88 adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Patients with one or more prior systemic therapies were also included, although they were not the primary target for the efficacy analysis.

The primary endpoints are safety and overall response rate (ORR), while secondary endpoints include complete response rate (CRR), duration of response (DOR), progression-free survival (PFS), PFS ratio, overall survival (OS), changes in health-related quality of life, and cellular dynamics.

In the primary efficacy analysis population of 74 patients (including only those who received 100 × 10⁶ CAR-expressing live T cells and had received two or more prior systemic therapies, including alkylating agents, Bruton’s tyrosine kinase inhibitors, and rituximab (or other CD20-targeted drugs)), the overall response rate (95% CI), which was the primary endpoint, was 86.5% (76.5–93.3), and the lower limit of the 95% CI was statistically significant against the pre-defined threshold of 40% (p<0.0001). In addition, in the efficacy analysis population of 77 patients (including those who received 100 × 10⁶ CAR-expressing live T cells and had received one or more prior systemic therapies), the ORR (95% CI) was 87.0% (77.4–93.6).
The safety profile was consistent with previously reported findings, and no new safety signals were observed.

(Press release, Bristol-Myers Squibb, APR 3, 2026, View Source [SID1234665483])

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

On April 3, 2026 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, reported that data from an investigator-initiated Phase II trial conducted at Memorial Sloan Kettering Cancer Center will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 17–22, 2026, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study evaluates botensilimab (BOT) and balstilimab (BAL) in combination with agenT-797, an allogeneic iNKT cell therapy developed by MiNK Therapeutics, in patients with PD-1 refractory gastroesophageal cancer (GEC)—an area of significant unmet need where resistance to checkpoint inhibition remains a major clinical challenge.

Presentation Details:

Abstract Title: A phase II study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in PD-1 refractory gastroesophageal cancer (GEC)

Presenter: Samuel L. Cytyrn, MD; Gastrointestinal Medical Oncologist, Memorial Sloan Kettering Cancer Center

Session Name: Phase II and Phase III Clinical Trials

Date/Time: April 20, 2026 | 2:00–5:00 PM PT; 5:00-8:00 PM EDT

Poster Section: 52

Abstract No.: CT166

(Press release, Agenus, APR 3, 2026, View Source [SID1234664170])

Syneron Bio Announces Completion of $150 Million Series B Financing

On April 3, 2026 Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, reported the successful closing of its Series B financing on March 31th. The round was led by an international life-science fund, with co-lead participation from Decheng Capital, and CDH VGC. Additional investors included a wholly owned subsidiary of the Abu Dhabi Investment Authority ("ADIA"), True Light Capital, — an independent, wholly-owned subsidiary of Temasek, Qiming Venture Partners, BioTrack Capital and well known industrial investors. Existing shareholders, including AstraZeneca, LAV, Sinovation Capital, 5Y Capital, GL Ventures, Biotech Development Fund and Lenovo Capital, among others, also continued their support.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds from this financing will be primarily used to further advance the intelligent evolution of the company’s proprietary macrocyclic peptide discovery platform, Synova, and to accelerate the progression of its diversified innovative pipeline into clinical development.

Dr. Frank Zhang, Founder and Chief Executive Officer of Syneron Bio, commented:

"We are honored to receive support and recognition in this financing round from a distinguished group of leading global healthcare funds, tech venture capitals, reputable multi-national corporations, and prominent sovereign wealth funds. The completion of this financing further strengthens our cash position, enabling us to accelerate the development of multiple core pipeline programs across oncology, autoimmune, metabolic, and rare diseases, with the goal of benefiting patients worldwide. At the same time, our high-throughput, intelligence-driven Synova platform will continue to scale and evolve, significantly improving the efficiency and success rate of macrocyclic peptide drug discovery. With the continued support of our capital and industry partners, we look forward to delivering innovative therapies and addressing critical unmet medical needs for patients around the globe."

(Press release, Syneron Bio, APR 3, 2026, View Source [SID1234664171])

Innate Pharma to Participate in the Kempen Life Sciences Conference

On April 3, 2026 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, reported that members of its executive team will participate in one-on-one investor meetings at the following conference:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kempen Life Sciences Conference

Dates: April 15 –16, 2026
Location: Amsterdam, Netherlands

(Press release, Innate Pharma, APR 3, 2026, View Source [SID1234664172])